Dopamine receptor partial agonists (DRPAs; aripiprazole, brexpiprazole, and cariprazine) constitute a novel class of antipsychotics. Although they share a similar mechanism of action, DRPAs differ in their pharmacodynamics, pharmacokinetics, drug interactions, or safety and tolerability. The antipsychotic efficacy of all three drugs was established in several placebo-controlled randomized trials (RCTs) in schizophrenia, both acute phase and relapse prevention. In addition, each of the DRPA agents has been tested in other psychiatric disorders, including bipolar disorder or major depression. However, a few studies have examined their comparative clinical efficacy. There are no head-to-head comparisons between aripiprazole, brexpiprazole, or cariprazine. In two acute schizophrenia RCTs of cariprazine and brexpiprazole, aripiprazole was used as an indirect comparator to control for study sensitivity. To assess potential differences in the efficacy of DRPAs, we reviewed data from controlled trials, systematic reviews, and meta-analyses. Our results showed that the acute antipsychotic effects of DRPAs, as measured by the number needed to treat, are comparable. The three agents were superior to placebo in acute treatment, and cariprazine was found to be effective in the reduction of primary negative symptoms of schizophrenia. In the therapy of bipolar disorder, aripiprazole and cariprazine showed antimanic efficacy, cariprazine was also effective in the management of bipolar depression, and aripiprazole was effective for relapse prevention. The addon administration of aripiprazole or brexpiprazole reduced symptoms of major depression. Aripiprazole can control acute agitation associated with psychosis or bipolar disorder; brexpiprazole showed the potential to manage agitation in dementia patients. Aripiprazole has also established evidence of efficacy in children and adolescents and other conditions: OCD, tic disorders, and autism spectrum disorder. Our review of published data suggests that in terms of clinical efficacy, DRPAs are a heterogeneous group, with each drug possessing its own therapeutic benefits.

Faculty of Medicine Charles University Prague Czechia

National Institute of Mental Health Klecany Czechia

Psychiatric Clinic of the University Hospital Hradec Kràlové Charles University Hradec Kràlové Czechia

Zobrazit více v PubMed

Keepers GA, Fochtmann LJ, Anzia JM, Benjamin S, Lyness JM, Mojtabai R, et al. . The American psychiatric association practice guideline for the treatment of patients with schizophrenia. Am J Psychiatry. (2020) 177:868–72. 10.1176/appi.ajp.2020.177901 PubMed DOI

Horacek J, Bubenikova-Valesova V, Kopecek M, Palenicek T, Dockery C, Mohr P, et al. . Mechanism of action of atypical antipsychotic drugs and the neurobiology of schizophrenia. CNS Drugs. (2006) 20:389–409. 10.2165/00023210-200620050-00004 PubMed DOI

Carlsson A. Dopamine receptor agonists: intrinsic activity vs. state of receptor. J Neural Transm. (1983) 57:309–15. 10.1007/BF01249001 PubMed DOI

Frankel JS, Schwartz TL. Brexpiprazole and cariprazine: distinguishing two new atypical antipsychotics from the original dopamine stabilizer aripiprazole. Ther Adv Psychopharmacol. (2017) 7:29–41. 10.1177/2045125316672136 PubMed DOI PMC

Besnard J, Ruda GF, Setola V, Abecassis K, Rodriguiz RM, Huang XP, et al. . Automated design of ligands to polypharmacological profiles. Nature. (2012) 492:215–20. 10.1038/nature11691 PubMed DOI PMC

Moore TJ, Glenmullen J, Mattison DR. Reports of pathological gambling, hypersexuality, and compulsive shopping associated with dopamine receptor agonist drugs. JAMA Intern Med. (2014) 174:1930–3. 10.1001/jamainternmed.2014.5262 PubMed DOI

Citrome L. The ABC's of dopamine receptor partial agonists - aripiprazole, brexpiprazole and cariprazine: the 15-min challenge to sort these agents out. Int J Clin Pract. (2015) 69:1211–20. 10.1111/ijcp.12752 PubMed DOI

Huhn M, Nikolakopoulou A, Schneider-Thoma J, Krause M, Samara M, Peter N, et al. . Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: a systematic review and network meta-analysis. Lancet. (2019) 394:939–51. 10.1016/S0140-6736(19)31135-3 PubMed DOI PMC

Findling RL, Robb A, Nyilas M, Forbes RA, Jin N, Ivanova S, et al. . A multiple-center, randomized, double-blind, placebo-controlled study of oral aripiprazole for treatment of adolescents with schizophrenia. Am J Psychiatry. (2008) 165:1432–41. 10.1176/appi.ajp.2008.07061035 PubMed DOI

Pigott TA, Carson WH, Saha AR, Torbeyns AF, Stock EG, Ingenito GG, et al. . Aripiprazole for the prevention of relapse in stabilized patients with chronic schizophrenia: a placebo-controlled 26-week study. J Clin Psychiatry. (2003) 64:1048–56. 10.4088/JCP.v64n0910 PubMed DOI

Kasper S, Lerman MN, McQuade RD, Saha A, Carson WH, Ali M, et al. . Efficacy and safety of aripiprazole vs. haloperidol for long-term maintenance treatment following acute relapse of schizophrenia. Int J Neuropsychopharmacol. (2003) 6:325–37. 10.1017/S1461145703003651 PubMed DOI

Fleischhacker WW, Hobart M, Ouyang J, Forbes A, Pfister S, McQuade RD, et al. . Efficacy and safety of brexpiprazole (OPC-34712) as maintenance treatment in adults with schizophrenia: a randomized, double-blind, placebo-controlled study. Int J Neuropsychopharmacol. (2017) 20:11–21. 10.1093/ijnp/pyw076 PubMed DOI PMC

Durgam S, Earley W, Li R, Li D, Lu K, Laszlovszky I, et al. . Long-term cariprazine treatment for the prevention of relapse in patients with schizophrenia: a randomized, double-blind, placebo-controlled trial. Schizophr Res. (2016) 176:264–71. 10.1016/j.schres.2016.06.030 PubMed DOI

Siskind DJ, Lee M, Ravindran A, Zhang Q, Ma E, Motamarri B, et al. . Augmentation strategies for clozapine refractory schizophrenia: a systematic review and meta-analysis. Aust N Z J Psychiatry. (2018) 52:751–67. 10.1177/0004867418772351 PubMed DOI

Németh G, Laszlovszky I, Czobor P, Szalai E, Szatmári B, Harsányi J, et al. . Cariprazine versus risperidone monotherapy for treatment of predominant negative symptoms in patients with schizophrenia: a randomised, double-blind, controlled trial. Lancet. (2017) 389:1103–13. 10.1016/S0140-6736(17)30060-0 PubMed DOI

Fountoulakis KN, Vieta E, Schmidt F. Aripiprazole monotherapy in the treatment of bipolar disorder: a meta-analysis. J Affect Disord. (2011) 133:361–70. 10.1016/j.jad.2010.10.018 PubMed DOI

Brown R, Taylor MJ, Geddes J. Aripiprazole alone or in combination for acute mania. Cochrane Database Syst Rev. (2013) 12:CD005000. 10.1002/14651858.CD005000.pub2 PubMed DOI PMC

Vieta E, Sachs G, Chang D, Hellsten J, Brewer C, Peters-Strickland T, et al. . Two randomized, double-blind, placebo-controlled trials and one open-label, long-term trial of brexpiprazole for the acute treatment of bipolar mania. J Psychopharmacol. (2021) 35:971–82. 10.1177/0269881120985102 PubMed DOI PMC

Earley W, Durgam S, Lu K, Ruth A, Németh G, Laszlovszky I, et al. . Clinically relevant response and remission outcomes in cariprazine-treated patients with bipolar I disorder. J Affect Disord. (2018) 226:239–44. 10.1016/j.jad.2017.09.040 PubMed DOI

Pinto JV, Saraf G, Vigo D, Keramatian K, Chakrabarty T, Yatham LN. Cariprazine in the treatment of bipolar disorder: a systematic review and meta-analysis. Bipolar Disord. (2020) 22:360–71. 10.1111/bdi.12850 PubMed DOI

Thase ME, Jonas A, Khan A, Bowden CL, Wu X, McQuade RD, et al. . Aripiprazole monotherapy in nonpsychotic bipolar I depression: results of 2 randomized, placebo-controlled studies. J Clin Psychopharmacol. (2008) 28:13–20. 10.1097/jcp.0b013e3181618eb4 PubMed DOI

U.S. National Library of Medicine. ClinicalTrials.gov . Available online at: https://clinicaltrials.gov/ (accessed November 20, 2021).

Keck PE, Calabrese JR, McQuade RD, Carson WH, Carlson BX, Rollin LM, et al. . A randomized, double-blind, placebo-controlled 26-week trial of aripiprazole in recently manic patients with bipolar I disorder. J Clin Psychiatry. (2006) 67:626–37. 10.4088/JCP.v67n0414 PubMed DOI

Keck PE, Calabrese JR, McIntyre RS, McQuade RD, Carson WH, Eudicone JM, et al. . Aripiprazole monotherapy for maintenance therapy in bipolar I disorder: a 100-week, double-blind study versus placebo. J Clin Psychiatry. (2007) 68:1480–91. 10.4088/JCP.v68n1003 PubMed DOI

Yatham LN, Fountoulakis KN, Rahman Z, Ammerman D, Fyans P, Marler SV, et al. . Efficacy of aripiprazole versus placebo as adjuncts to lithium or valproate in relapse prevention of manic or mixed episodes in bipolar I patients stratified by index manic or mixed episode. J Affect Disord. (2013) 147:365–72. 10.1016/j.jad.2012.11.042 PubMed DOI

Findling RL, Nyilas M, Forbes RA, McQuade RD, Jin N, Iwamoto T, et al. . Acute treatment of pediatric bipolar I disorder, manic or mixed episode, with aripiprazole: a randomized, double-blind, placebo-controlled study. J Clin Psychiatry. (2009) 70:1441–51. 10.4088/JCP.09m05164yel PubMed DOI

Findling RL, Correll CU, Nyilas M, Forbes RA, McQuade RD, Jin N, et al. . Aripiprazole for the treatment of pediatric bipolar I disorder: a 30-week, randomized, placebo-controlled study. Bipolar Disord. (2013) 15:138–49. 10.1111/bdi.12042 PubMed DOI

Findling RL, Youngstrom EA, McNamara NK, Stansbrey RJ, Wynbrandt JL, Adegbite C, et al. . Double-blind, randomized, placebo-controlled long-term maintenance study of aripiprazole in children with bipolar disorder. J Clin Psychiatry. (2012) 73:57–63. 10.4088/JCP.11m07104 PubMed DOI

Tramontina S, Zeni CP, Ketzer CR, Pheula GF, Narvaez J, Rohde LA. Aripiprazole in children and adolescents with bipolar disorder comorbid with attention-deficit/hyperactivity disorder: a pilot randomized clinical trial. J Clin Psychiatry. (2009) 70:756–64. 10.4088/JCP.08m04726 PubMed DOI

Findling RL, Youngstrom EA, Rowles BM, Deyling E, Lingler J, Stansbrey RJ, et al. . A double-blind and placebo-controlled trial of aripiprazole in symptomatic youths at genetic high risk for bipolar disorder. J Child Adolesc Psychopharmacol. (2017) 27:864–74. 10.1089/cap.2016.0160 PubMed DOI

Nelson JC, Thase ME, Bellocchio EE, Rollin LM, Eudicone JM, McQuade RD, et al. . Efficacy of adjunctive aripiprazole in patients with major depressive disorder who showed minimal response to initial antidepressant therapy. Int Clin Psychopharmacol. (2012) 27:125–33. 10.1097/YIC.0b013e3283502791 PubMed DOI

Kishi T, Sakuma K, Nomura I, Matsuda Y, Mishima K, Iwata N. Brexpiprazole as adjunctive treatment for major depressive disorder following treatment failure with at least one antidepressant in the current episode: a systematic review and meta-analysis. Int J Neuropsychopharmacol. (2019) 22:698–709. 10.1093/ijnp/pyz040 PubMed DOI PMC

Durgam S, Earley W, Guo H, Li D, Németh G, Laszlovszky I, et al. . Efficacy and safety of adjunctive cariprazine in inadequate responders to antidepressants: a randomized, double-blind, placebo-controlled study in adult patients with major depressive disorder. J Clin Psychiatry. (2016) 77:371–8. 10.4088/JCP.15m10070 PubMed DOI

Earley WR, Guo H, Németh G, Harsányi J, Thase ME. Cariprazine augmentation to antidepressant therapy in major depressive disorder: results of a randomized, double-blind, placebo-controlled trial. Psychopharmacol Bull. (2018) 48:62–80. PubMed PMC

Fava M, Durgam S, Earley W, Lu K, Hayes R, Laszlovszky I, et al. . Efficacy of adjunctive low-dose cariprazine in major depressive disorder: a randomized, double-blind, placebo-controlled trial. Int Clin Psychopharmacol. (2018) 33:312–21. 10.1097/YIC.0000000000000235 PubMed DOI PMC

De Deyn PP, Drenth AF, Kremer BP, Oude Voshaar RC, Van Dam D. Aripiprazole in the treatment of Alzheimer's disease. Expert Opin Pharmacother. (2013) 14:459–74. 10.1517/14656566.2013.764989 PubMed DOI

De Deyn P, Jeste DV, Swanink R, Kostic D, Breder C, Carson WH, et al. . Aripiprazole for the treatment of psychosis in patients with Alzheimer's disease: a randomized, placebo-controlled study. J Clin Psychopharmacol. (2005) 25:463–7. 10.1097/01.jcp.0000178415.22309.8f PubMed DOI

Streim JE, Porsteinsson AP, Breder CD, Swanink R, Marcus R, McQuade R, et al. . randomized, double-blind, placebo-controlled study of aripiprazole for the treatment of psychosis in nursing home patients with Alzheimer disease. Am J Geriatr Psychiatry. (2008) 16:537–50. 10.1097/JGP.0b013e318165db77 PubMed DOI

Mintzer JE, Tune LE, Breder CD, Swanink R, Marcus RN, McQuade RD, et al. . Aripiprazole for the treatment of psychoses in institutionalized patients with Alzheimer dementia: a multicenter, randomized, double-blind, placebo-controlled assessment of three fixed doses. Am J Geriatr Psychiatry. (2007) 15:918–31. 10.1097/JGP.0b013e3181557b47 PubMed DOI

Grossberg GT, Kohegyi E, Mergel V, Josiassen MK, Meulien D, Hobart M, et al. . Efficacy and safety of brexpiprazole for the treatment of agitation in Alzheimer's dementia: two 12-week, randomized, double-blind, placebo-controlled trials. Am J Geriatr Psychiatry. (2020) 28:383–400. 10.1016/j.jagp.2019.09.009 PubMed DOI

Muscatello MR, Bruno A, Pandolfo G, Micò U, Scimeca G, Romeo VM, et al. . Effect of aripiprazole augmentation of serotonin reuptake inhibitors or clomipramine in treatment-resistant obsessive-compulsive disorder: a double-blind, placebo-controlled study. J Clin Psychopharmacol. (2011) 31:174–9. 10.1097/JCP.0b013e31820e3db6 PubMed DOI

Sayyah M, Sayyah M, Boostani H, Ghaffari SM, Hoseini A. Effects of aripiprazole augmentation in treatment-resistant obsessive-compulsive disorder (a double blind clinical trial). Depress Anxiety. (2012) 29:850–4. 10.1002/da.21996 PubMed DOI

Selvi Y, Atli A, Aydin A, Besiroglu L, Ozdemir P, Ozdemir O. The comparison of aripiprazole and risperidone augmentation in selective serotonin reuptake inhibitor-refractory obsessive-compulsive disorder: a single-blind, randomised study. Hum Psychopharmacol. (2011) 26:51–7. 10.1002/hup.1169 PubMed DOI

Shoja Shafti S, Kaviani H. Aripiprazole versus quetiapine in treatment-resistant obsessive-compulsive disorder: a double-blind clinical trial. Ther Adv Psychopharmacol. (2015) 5:32–7. 10.1177/2045125314560739 PubMed DOI PMC

Zhou DD, Zhou XX, Lv Z, Chen XR, Wang W, Wang GM, et al. . Comparative efficacy and tolerability of antipsychotics as augmentations in adults with treatment-resistant obsessive-compulsive disorder: a network meta-analysis. J Psychiatr Res. (2019) 111:51–8. 10.1016/j.jpsychires.2019.01.014 PubMed DOI

Wang S, Wei YZ, Yang JH, Zhou YM, Cheng YH, Yang C, et al. . The efficacy and safety of aripiprazole for tic disorders in children and adolescents: a systematic review and meta-analysis. Psychiatry Res. (2017) 254:24–32. 10.1016/j.psychres.2017.04.013 PubMed DOI

Yang C, Hao Z, Zhang LL, Zhu CR, Zhu P, Guo Q. Comparative efficacy and safety of antipsychotic drugs for tic disorders: a systematic review and Bayesian network meta-analysis. Pharmacopsychiatry. (2019) 52:7–15. 10.1055/s-0043-124872 PubMed DOI

Maneeton N, Maneeton B, Putthisri S, Suttajit S, Likhitsathian S, Srisurapanont M. Aripiprazole in acute treatment of children and adolescents with autism spectrum disorder: a systematic review and meta-analysis. Neuropsychiatr Dis Treat. (2018) 14:3063–72. 10.2147/NDT.S174622 PubMed DOI PMC

Brunetti M, Di Tizio L, Dezi S, Pozzi G, Grandinetti P, Martinotti G. Aripiprazole, alcohol and substance abuse: a review. Eur Rev Med Pharmacol Sci. (2012) 16:1346–54. PubMed

Krause M, Huhn M, Schneider-Thoma J, Bighelli I, Gutsmiedl K, Leucht S. Efficacy, acceptability and tolerability of antipsychotics in patients with schizophrenia and comorbid substance use. A systematic review and meta-analysis. Eur Neuropsychopharmacol. (2019) 29:32–45. 10.1016/j.euroneuro.2018.11.1105 PubMed DOI

Martinotti G, Orsolini L, Fornaro M, Vecchiotti R, De Berardis D, Iasevoli F, et al. . Aripiprazole for relapse prevention and craving in alcohol use disorder: current evidence and future perspectives. Expert Opin Investig Drugs. (2016) 25:719–28. 10.1080/13543784.2016.1175431 PubMed DOI

Anton RF, Kranzler H, Breder C, Marcus RN, Carson WH, Han J, et al. . randomized, multicenter, double-blind, placebo-controlled study of the efficacy and safety of aripiprazole for the treatment of alcohol dependence. J Clin Psychopharmacol. (2008) 28:5–12. 10.1097/jcp.0b013e3181602fd4 PubMed DOI

Martinotti G, Di Nicola M, Di Giannantonio M, Janiri L. Aripiprazole in the treatment of patients with alcohol dependence: a double-blind, comparison trial vs. naltrexone. J Psychopharmacol. (2009) 23:123–9. 10.1177/0269881108089596 PubMed DOI

Kane JM, Peters-Strickland T, Baker RA, Hertel P, Eramo A, Jin N, et al. . Aripiprazole once-monthly in the acute treatment of schizophrenia: findings from a 12-week, randomized, double-blind, placebo-controlled study. J Clin Psychiatry. (2014) 75:1254–60. 10.4088/JCP.14m09168 PubMed DOI

Meltzer HY, Risinger R, Nasrallah HA, Du Y, Zummo J, Corey L, et al. . A randomized, double-blind, placebo-controlled trial of aripiprazole lauroxil in acute exacerbation of schizophrenia. J Clin Psychiatry. (2015) 76:1085–90. 10.4088/JCP.14m09741 PubMed DOI

Kane JM, Sanchez R, Perry PP, Jin N, Johnson BR, Forbes RA, et al. . Aripiprazole intramuscular depot as maintenance treatment in patients with schizophrenia: a 52-week, multicenter, randomized, double-blind, placebo-controlled study. J Clin Psychiatry. (2012) 73:617–24. 10.4088/JCP.11m07530 PubMed DOI

Fleischhacker WW, Sanchez R, Perry PP, Jin N, Peters-Strickland T, Johnson BR, et al. . Aripiprazole once-monthly for treatment of schizophrenia: double-blind, randomised, non-inferiority study. Br J Psychiatry. (2014) 205:135–44. 10.1192/bjp.bp.113.134213 PubMed DOI

Ishigooka J, Nakamura J, Fujii Y, Iwata N, Kishimoto T, Iyo M, et al. . Efficacy and safety of aripiprazole once-monthly in Asian patients with schizophrenia: a multicenter, randomized, double-blind, non-inferiority study versus oral aripiprazole. Schizophr Res. (2015) 161:421–8. 10.1016/j.schres.2014.12.013 PubMed DOI

Calabrese JR, Sanchez R, Jin N, Amatniek J, Cox K, Johnson B, et al. . Efficacy and safety of aripiprazole once-monthly in the maintenance treatment of bipolar I disorder: a double-blind, placebo-controlled, 52-week randomized withdrawal study. J Clin Psychiatry. (2017) 78:324–31. 10.4088/JCP.16m11201 PubMed DOI

Calabrese JR, Sanchez R, Jin N, Amatniek J, Cox K, Johnson B, et al. . Symptoms and functioning with aripiprazole once-monthly injection as maintenance treatment for bipolar I disorder. J Affect Disord. (2018) 227:649–56. 10.1016/j.jad.2017.10.035 PubMed DOI

Naber D, Hansen K, Forray C, Baker RA, Sapin C, Beillat M, et al. . Qualify: a randomized head-to-head study of aripiprazole once-monthly and paliperidone palmitate in the treatment of schizophrenia. Schizophr Res. (2015) 168:498–504. 10.1016/j.schres.2015.07.007 PubMed DOI

Cuomo I, Kotzalidis GD, de Persis S, Piacentino D, Perrini F, Amici E, et al. . Head-to-head comparison of 1-year aripiprazole long-acting injectable (LAI) versus paliperidone LAI in comorbid psychosis and substance use disorder: impact on clinical status, substance craving, and quality of life. Neuropsychiatr Dis Treat. (2018) 14:1645–56. 10.2147/NDT.S171002 PubMed DOI PMC

Andrezina R, Josiassen RC, Marcus RN, Oren DA, Manos G, Stock E, et al. . Intramuscular aripiprazole for the treatment of acute agitation in patients with schizophrenia or schizoaffective disorder: a double-blind, placebo-controlled comparison with intramuscular haloperidol. Psychopharmacology (Berl). (2006) 188:281–92. 10.1007/s00213-006-0541-x PubMed DOI

Tran-Johnson TK, Sack DA, Marcus RN, Auby P, McQuade RD, Oren DA. Efficacy and safety of intramuscular aripiprazole in patients with acute agitation: a randomized, double-blind, placebo-controlled trial. J Clin Psychiatry. (2007) 68:111–9. 10.4088/JCP.v68n0115 PubMed DOI

Zimbroff DL, Marcus RN, Manos G, Stock E, McQuade RD, Auby P, et al. . Management of acute agitation in patients with bipolar disorder: efficacy and safety of intramuscular aripiprazole. J Clin Psychopharmacol. (2007) 27:171–6. 10.1097/JCP.0b13e318033bd5e PubMed DOI

Rappaport SA, Marcus RN, Manos G, McQuade RD, Oren DA. A randomized, double-blind, placebo-controlled tolerability study of intramuscular aripiprazole in acutely agitated patients with Alzheimer's, vascular, or mixed dementia. J Am Med Dir Assoc. (2009) 10:21–7. 10.1016/j.jamda.2008.06.006 PubMed DOI

Durgam S, Cutler AJ, Lu K, Migliore R, Ruth A, Laszlovszky I, et al. . Cariprazine in acute exacerbation of schizophrenia: a fixed-dose, phase 3, randomized, double-blind, placebo- and active-controlled trial. J Clin Psychiatry. (2015) 76:e1574–82. 10.4088/JCP.15m09997 PubMed DOI

Citrome L, Ota A, Nagamizu K, Perry P, Weiller E, Baker RA. The effect of brexpiprazole (OPC-34712) and aripiprazole in adult patients with acute schizophrenia: results from a randomized, exploratory study. Int Clin Psychopharmacol. (2016) 31:192–201. 10.1097/YIC.0000000000000123 PubMed DOI

Citrome L. Aripiprazole, brexpiprazole, and cariprazine: not all the same. Curr Psychiatr. (2018) 17:24–34.

Vázquez GH, Bahji A, Undurraga J, Tondo L, Baldessarini RJ. Efficacy and tolerability of combination treatments for major depression: antidepressants plus second-generation antipsychotics vs. esketamine vs. lithium. J Psychopharmacol. (2021) 35:890–900. 10.1177/02698811211013579 PubMed DOI PMC

Vázquez GH, Holtzman JN, Tondo L, Baldessarini RJ. Efficacy and tolerability of treatments for bipolar depression. J Affect Disord. (2015) 183:258–62. 10.1016/j.jad.2015.05.016 PubMed DOI

Kadakia A, Dembek C, Heller V, Singh R, Uyei J, Hagi K, et al. . Efficacy and tolerability of atypical antipsychotics for acute bipolar depression: a network meta-analysis. BMC Psychiatry. (2021) 21:249. 10.1186/s12888-021-03220-3 PubMed DOI PMC

Citrome L. Cariprazine for bipolar depression: What is the number needed to treat, number needed to harm and likelihood to be helped or harmed? Int J Clin Pract. (2019) 73:e13397. 10.1111/ijcp.13397 PubMed DOI

Kishi T, Ikuta T, Matsuda Y, Sakuma K, Iwata N. Aripiprazole vs. brexpiprazole for acute schizophrenia: a systematic review and network meta-analysis. Psychopharmacology (Berl). (2020) 237:1459–70. 10.1007/s00213-020-05472-5 PubMed DOI

Yildiz A, Nikodem M, Vieta E, Correll CU, Baldessarini RJ. A network meta-analysis on comparative efficacy and all-cause discontinuation of antimanic treatments in acute bipolar mania. Psychol Med. (2015) 45:299–317. 10.1017/S0033291714001305 PubMed DOI

Keks N, Hope J, Schwartz D, McLennan H, Copolov D, Meadows G. Comparative tolerability of dopamine D2/3 receptor partial agonists for schizophrenia. CNS Drugs. (2020) 34:473–507. 10.1007/s40263-020-00718-4 PubMed DOI

Zazu L, Morera-Herreras T, Garcia M, Aguirre C, Lertxundi U. Do cariprazine and brexpiprazole cause impulse control symptoms? A case/non-case study. Eur Neuropsychopharmacol. (2021) 50:107–11. 10.1016/j.euroneuro.2021.05.001 PubMed DOI

Citrome L, Kantrowitz J. Antipsychotics for the treatment of schizophrenia: likelihood to be helped or harmed, understanding proximal and distal benefits and risks. Expert Rev Neurother. (2008) 8:1079–91. 10.1586/14737175.8.7.1079 PubMed DOI

Corponi F, Fabbri C, Bitter I, Montgomery S, Vieta E, Kasper S, et al. . Novel antipsychotics specificity profile: a clinically oriented review of lurasidone, brexpiprazole, cariprazine and lumateperone. Eur Neuropsychopharmacol. (2019) 29:971–85. 10.1016/j.euroneuro.2019.06.008 PubMed DOI

Schoemaker H, Claustre Y, Fage D, Rouquier L, Chergui K, Curet O, et al. . Neurochemical characteristics of amisulpride, an atypical dopamine D2/D3 receptor antagonist with both presynaptic and limbic selectivity. J Pharmacol Exp Ther. (1997) 280:83–97. PubMed

Krause M, Zhu Y, Huhn M, Schneider-Thoma J, Bighelli I, Nikolakopoulou A, et al. . Antipsychotic drugs for patients with schizophrenia and predominant or prominent negative symptoms: a systematic review and meta-analysis. Eur Arch Psychiatry Clin Neurosci. (2018) 268:625–39. 10.1007/s00406-018-0869-3 PubMed DOI

Mohr P, Czobor P. Subject selection for the placebo- and comparator-controlled trials of neuroleptics in schizophrenia. J Clin Psychopharmacol. (2000) 20:240–5. 10.1097/00004714-200004000-00018 PubMed DOI

Challenges in defining treatment-resistant mania in adults: A systematic review

Impact of cognitive performance and negative symptoms on psychosocial functioning in Czech schizophrenia patients